Evaluation of Skin Quality Improvement

Steve Yoelin M.D. Medical Associates, Inc.15 enrolled

Overview

The purpose of this study is to comprehensively investigate and objectively demonstrate the effectiveness of hyperdiltue Botox® Cosmetic in improving overall skin quality, more specifically evenness of skin tone, reduction of pore size and improvement in the appearance of preexisting skin scars. The ability of hyperdilute Botox® Cosmetic to improve overall skin quality is likely optimized when it is injected uniformly in hyper-diluted small aliquots in order to "saturate" the dermis. We propose to prepare Botox® Cosmetic in a manner that is approximately 4 times more dilute compared to the typical Botox® Cosmetic preparation. A 4x4 centimeter area located in the mid-cheek adjacent to the nose will be injected with hyperdilute Botox® Cosmetic. Botox® Cosmetic is not FDA-approved for this use. A maximum of 15 subjects will participate in this study, all of whom will receive injections of Botox® Cosmetic during the course of this study. This study is a randomized, placebo-controlled, and double-masked study. This means neither the study doctor nor participant know the experimental agent (e.g., 0.9% saline solution and hyperdiluted Botox® Cosmetic) injected on each side of the patients' faces. The study will last for a total of 75 days. Evaluation of the study is based on the analysis of photographic images obtained during the study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Skin Quality

Interventions

Hyper-Diluted BotoxDRUG

0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½" needle

Topical anesthesiaDRUG

Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes

0.9% saline solutionOTHER

0.1ml of 0.9% saline solution will be administered to the side of the face

Eligibility

Sex: ALLMin age: 35 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Ability to follow study instructions and likely to complete all required visits * Written consent has been obtained * Written authorization for "Use and Release of Health and Research Study Information" has been obtained * Subjects who are Fitzpatrick Skin Types II-IV Exclusion Criteria: * Subjects must be Onabotulinum Toxin Type A naive; if subject has had Onabotulinum Toxin Type A administered in the face in the previous 12 months they are excluded * Subjects must be dermal filler naïve in the lateral canthal region and midface regions * Subjects must be energy or light device naïve * Subjects must have average or below-average lifetime sun exposure * Subjects must be free of inflammatory skin disease(s)

Locations (1)

Steve Yoelin MD & Associates

Newport Beach, California, United States

Outcomes

Primary Outcomes

Percent Improvement in Skin Quality

An evaluation of the percent improvement in skin quality when the "Onabotulinum Toxin Type A" treated side of face is compared to the "placebo" treated side of the face. Good skin quality is defined as small pore size, evenness of skin texture, evenness of skin tone, minimal presence of wrinkles, and minimal presence of scars. We will measure improvement primarily by image analysis of the photos taken during each visit using the Canfield Scientific camera (or the Allergan provided alternative).

Time frame: Entire duration of the study (Day 1-Day 135)

Secondary Outcomes

Patient and Investigator Reported Outcomes

An objective observer as well as the patient will evaluate if there is an improvement in skin quality throughout the course of the study.

Time frame: Entire duration of the study (Day 1-Day 135)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.